Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

FaR-RMS: Frontline and Relapse Study in RhabdomyoSarcoma Study


Status: Open | NSW , VIC , WA , New Zealand

Patients diagnosed with rhabdomyosarcoma are treated with chemotherapy, radiotherapy and surgery, but many do not survive. Our United Kingdom and European colleagues have developed a new overarching trial, FaR-RMS study, which includes optimising radiotherapy, testing the latest promising agents, new combinations and analysing the length of therapy. Several research questions are addressed within FaR-RMS and new drugs can be rapidly added. Opening FaR-RMS in Australia gives new hope to all patients battling rhabdomyosarcoma.

Disease Stage: Newly diagnosed, relapsed and progressive

Patient Age Range: All ages

Trial Sponsors:

  • International: University of Birmingham
  • National: ANZCHOG

ANZCHOG acknowledges the valuable support of FaR-RMS by the Australian Government through the Medical Research Future Fund.